Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
7.84 (CAD) • At close June 30, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CAD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.235 | 0.21 | 0.193 | 0.112 | 0.117 | 0.202 | 0.126 | 0.085 |
| Gross Profit
| -0.235 | -0.21 | -0.193 | -0.112 | -0.117 | -0.202 | -0.126 | -0.085 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 21.834 | 27.544 | 17.203 | 9.679 | 0.86 | 2.942 | 6.645 | 3.186 |
| General & Administrative Expenses
| 0 | 9.651 | 5.808 | 8.887 | 1.27 | 3.015 | 7.544 | 1.699 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 14.924 | 9.651 | 5.808 | 8.887 | 1.27 | 3.015 | 7.544 | 1.699 |
| Other Expenses
| 0 | 0 | 0 | -2.26 | 0 | 0.002 | 0 | 0 |
| Operating Expenses
| 36.758 | 37.924 | 23.204 | 18.678 | 2.246 | 6.159 | 14.315 | 4.971 |
| Operating Income
| -36.994 | -36.897 | -22.635 | -20.872 | -2.246 | -6.146 | -14.314 | -4.971 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.727 | -2.288 | -0.064 | -5.46 | -1.764 | -1.082 | -2.949 | -0.143 |
| Income Before Tax
| -35.266 | -39.185 | -23.917 | -23.37 | -4.011 | -7.241 | -14.833 | -4.998 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.002 | -0.09 | 0.931 | -1.344 | 1.868 | 1.399 | -1.459 | -0.628 |
| Net Income
| -34.937 | -37.392 | -23.259 | -22.99 | -3.997 | -7.176 | -13.232 | -4.318 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.03 | -1.58 | -1.21 | -1.61 | -0.31 | -0.56 | -1.03 | -0.34 |
| EPS Diluted
| -1.03 | -1.58 | -1.21 | -1.61 | -0.31 | -0.56 | -1.03 | -0.34 |
| EBITDA
| -33.717 | -37.395 | -22.136 | -21.961 | -2.012 | -5.945 | -14.565 | -4.885 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |